PMC:7200337 / 77757-78030 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T460","span":{"begin":33,"end":41},"obj":"Disease"},{"id":"T461","span":{"begin":264,"end":271},"obj":"Disease"}],"attributes":[{"id":"A460","pred":"mondo_id","subj":"T460","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A461","pred":"mondo_id","subj":"T461","obj":"http://purl.obolibrary.org/obo/MONDO_0005271"}],"text":"all RCT in China with 237 severe COVID-19 patients randomized 2:1 to remdesivir versus placebo demonstrated no significant benefit in time to clinical improvement (Wang et al., 2020g). Almost simultaneously, preliminary results from a larger National Institute of Allergy a"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T875","span":{"begin":233,"end":234},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"all RCT in China with 237 severe COVID-19 patients randomized 2:1 to remdesivir versus placebo demonstrated no significant benefit in time to clinical improvement (Wang et al., 2020g). Almost simultaneously, preliminary results from a larger National Institute of Allergy a"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T78854","span":{"begin":69,"end":79},"obj":"Chemical"}],"attributes":[{"id":"A67089","pred":"chebi_id","subj":"T78854","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"all RCT in China with 237 severe COVID-19 patients randomized 2:1 to remdesivir versus placebo demonstrated no significant benefit in time to clinical improvement (Wang et al., 2020g). Almost simultaneously, preliminary results from a larger National Institute of Allergy a"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T47","span":{"begin":264,"end":271},"obj":"Phenotype"}],"attributes":[{"id":"A47","pred":"hp_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/HP_0012393"}],"text":"all RCT in China with 237 severe COVID-19 patients randomized 2:1 to remdesivir versus placebo demonstrated no significant benefit in time to clinical improvement (Wang et al., 2020g). Almost simultaneously, preliminary results from a larger National Institute of Allergy a"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2533","span":{"begin":139,"end":141},"obj":"Gene"},{"id":"2534","span":{"begin":66,"end":68},"obj":"Gene"},{"id":"2540","span":{"begin":42,"end":50},"obj":"Species"},{"id":"2548","span":{"begin":69,"end":79},"obj":"Chemical"},{"id":"2553","span":{"begin":33,"end":41},"obj":"Disease"},{"id":"2554","span":{"begin":264,"end":271},"obj":"Disease"}],"attributes":[{"id":"A2533","pred":"tao:has_database_id","subj":"2533","obj":"Gene:6999"},{"id":"A2534","pred":"tao:has_database_id","subj":"2534","obj":"Gene:6999"},{"id":"A2540","pred":"tao:has_database_id","subj":"2540","obj":"Tax:9606"},{"id":"A2548","pred":"tao:has_database_id","subj":"2548","obj":"MESH:C000606551"},{"id":"A2553","pred":"tao:has_database_id","subj":"2553","obj":"MESH:C000657245"},{"id":"A2554","pred":"tao:has_database_id","subj":"2554","obj":"MESH:D004342"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"all RCT in China with 237 severe COVID-19 patients randomized 2:1 to remdesivir versus placebo demonstrated no significant benefit in time to clinical improvement (Wang et al., 2020g). Almost simultaneously, preliminary results from a larger National Institute of Allergy a"}